Kitasato University Professor in Japan Suggests WHO & Regulators Not Ignore Ivermectin Positive Data

CVT Cases Turn up in Patients Vaccinated with mRNA-based Vaccine: a Black Swan or Predictable Event?

Morimasa Yagisawa, visiting professor at Kitasato University, Omura Satoshi Memorial Institute in Tokyo, went on the record that the World Health Organization, drug regulators, and health policy makers shouldn’t ignore anymore the growing data that ivermectin can be an effective and safe adjuvant treatment for COVID-19. Citing accumulating clinical trials data, including many doctor-initiated studies, the professor cited in a virtual interview that 105 studies of ivermectin associated with the coronavirus across 32 nations have been registered, of which 24 have been completed and published. The professor declared that “ivermectin is almighty for prophylaxis, for treatment of early and late stage, and also for long COVID-19 (or) post-acute sequelae (of SARS-CoV-2).” 

Yagisawa is one of four authors that produced a report titled “Global trends in clinical studies of ivermectin in COVID-19” published in March in the “Japanese Journal of Antibiotics.” He was joined in that report by Satoshi Omura, the biochemist, along with William Campbell who was awarded the 2015 Nobel Prize in Physiology or Medicine associated with the discovery of avermectin, the derivative of which ivermectin ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee